Lipids and Diabetic Retinopathy

REFERENCES

• Public health focus: prevention of blindness associated with diabetic retinopathy. Morbid Mortal Weekly Rep 1993;42(10):191–195
   PubMedGoogle Scholar
• Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122(4):552–563
   PubMed Web of Science ®Google Scholar
• Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. J Am Med Assoc 2010;304(6):649–656
   PubMed Web of Science ®Google Scholar
• Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998;39(2):233–252
   PubMed Web of Science ®Google Scholar
• Zander E, Herfurth S, Bohl B, et al. Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Br J Ophthalmol 2000;84(8):871–876
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239
   PubMed Web of Science ®Google Scholar
• Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009;10(2):109–121
   PubMed Web of Science ®Google Scholar
• Keiding NR, Mann GV, Root HF, et al. Serum lipoproteins and cholesterol levels in normal subjects and in young patients with diabetes in relation to vascular complications. Diabetes 1952;1(6):434–440
   PubMed Web of Science ®Google Scholar
• Kissebah AH, Kohner EM, Lewis B, et al. Plasma-lipids and glucose/insulin relationship in non-insulin-requiring diabetics with and without retinopathy. Lancet 1975;1(7916):1104–1108
   PubMed Web of Science ®Google Scholar
• Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991;98(8):1261–1265
   PubMed Web of Science ®Google Scholar
• Klein BE, Myers CE, Howard KP, Klein R. Serum lipids and proliferative diabetic retinopathy and macular edema in persons with long-term type 1 diabetes mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. JAMA Ophthalmol 2015;133(5):503–510
   PubMed Web of Science ®Google Scholar
• Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244
   PubMed Web of Science ®Google Scholar
• Cetin EN, Bulgu Y, Ozdemir S, et al. Association of serum lipid levels with diabetic retinopathy. Int J Ophthalmol 2013;6(3):346–349
   PubMed Web of Science ®Google Scholar
• Leung H, Wang JJ, Rochtchina E, et al. Dyslipidaemia and microvascular disease in the retina. Eye (Lond) 2005;19(8):861–868
   PubMed Web of Science ®Google Scholar
• Morton J, Zoungas S, Li Q, et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2012;35(11):2201–2206
   PubMed Web of Science ®Google Scholar
• Chew EY, Klein ML, Ferris FL, 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114(9):1079–1084
   PubMedGoogle Scholar
• Fong DS, Ferris FL, 3rd, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1999;127(2):137–141
   PubMed Web of Science ®Google Scholar
• Lloyd CE, Klein R, Maser RE, et al. The progression of retinopathy over 2 years: The Pittsburgh Epidemiology of Diabetes Complications (EDC) study. J Diabetes Complications 1995;9(3):140–148
   PubMed Web of Science ®Google Scholar
• van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: The Hoorn Study. Diabetes Care 2002;25(8):1320–1325
   PubMed Web of Science ®Google Scholar
• Cohen RA, Hennekens CH, Christen WG, et al. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999;107(1):45–51
   PubMed Web of Science ®Google Scholar
• Romero P, Salvat M, Fernandez J, et al. Renal and retinal microangiopathy after 15 years of follow-up study in a sample of type 1 diabetes mellitus patients. J Diabetes Complications 2007;21(2):93–100
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990;13(7):741–747
   PubMed Web of Science ®Google Scholar
• Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995;102(4):647–661
   PubMed Web of Science ®Google Scholar
• Sjolie AK, Stephenson J, Aldington S, et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 1997;104(2):252–260
   PubMed Web of Science ®Google Scholar
• Weber B, Burger W, Hartmann R, et al. Risk factors for the development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1986;29(1):23–29
   PubMed Web of Science ®Google Scholar
• Miljanovic B, Glynn RJ, Nathan DM, et al. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004;53(11):2883–2892
   PubMed Web of Science ®Google Scholar
• Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 2014;129(9):999–1008
   PubMed Web of Science ®Google Scholar
• Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004;45(3):910–918
   PubMed Web of Science ®Google Scholar
• Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990;10(6):1067–1073
   PubMedGoogle Scholar
• Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 18 1996;276(11):875–881
   PubMed Web of Science ®Google Scholar
• Kao YL, Donaghue K, Chan A, et al. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 1998;83(7):2589–2592
   PubMed Web of Science ®Google Scholar
• Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care 2011;34(2):474–479
   PubMed Web of Science ®Google Scholar
• Lopes-Virella MF, Baker NL, Hunt KJ, et al. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care 2012;35(6):1333–1340
   PubMed Web of Science ®Google Scholar
• Ferre R, Aragones G, Plana N, et al. High-density lipoprotein cholesterol and apolipoprotein A1 levels strongly influence the reactivity of small peripheral arteries. Atherosclerosis 2011;216(1):115–119
   PubMed Web of Science ®Google Scholar
• Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoproteins are associated with systemic and retinal microvascular function in persons with diabetes. Diabetes 2012;61(7):1785--1792
   PubMed Web of Science ®Google Scholar
• Kawai S, Nakajima T, Hokari S, et al. Apolipoprotein A-I concentration in tears in diabetic retinopathy. Ann Clin Biochem 2002;39(Pt 1):56–61
   PubMed Web of Science ®Google Scholar
• Simo R, Higuera M, Garcia-Ramirez M, et al. Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. Arch Ophthalmol 2008;126(8):1076–1081
   PubMedGoogle Scholar
• Garcia-Ramirez M, Canals F, Hernandez C, et al. Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007;50(6):1294–1303
   PubMed Web of Science ®Google Scholar
• Tserentsoodol N, Gordiyenko NV, Pascual I, et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol Vis 2006;12:1319–1333
   PubMed Web of Science ®Google Scholar
• Ishida BY, Duncan KG, Bailey KR, et al. High density lipoprotein mediated lipid efflux from retinal pigment epithelial cells in culture. Br J Ophthalmol 2006;90(5):616–620
   PubMed Web of Science ®Google Scholar
• Ng DS, O'Connor PW, Mortimer CB, et al. Case report: retinopathy and neuropathy associated with complete apolipoprotein A-I deficiency. Am J Med Sci 1996;312(1):30–33
   PubMed Web of Science ®Google Scholar
• Ng DS, Leiter LA, Vezina C, et al. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994;93(1):223–229
   PubMed Web of Science ®Google Scholar
• Robbesyn F, Auge N, Vindis C, et al. High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arteriosclerosis Thrombosis Vasc Biol 2005;25(6):1206–1212
   PubMed Web of Science ®Google Scholar
• Lyons TJ, Baynes JW, Patrick JS, et al. Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia 1986;29(10):685–689
   PubMed Web of Science ®Google Scholar
• Pennathur S, Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxidants Redox Signal 2007;9(7):955–969
   PubMed Web of Science ®Google Scholar
• Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49(6):2679–2685
   PubMed Web of Science ®Google Scholar
• Schreurs MP, Hubel CA, Bernstein IM, et al. Increased oxidized low-density lipoprotein causes blood–brain barrier disruption in early-onset preeclampsia through LOX-1. FASEB J 2013;27(3):1254–1263
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SJ, Kim KW, Yu YS. Oxidized low density lipoprotein-induced senescence of retinal pigment epithelial cells is followed by outer blood–retinal barrier dysfunction. Int J Biochem Cell Biol 2012;44(5):808–814
   PubMed Web of Science ®Google Scholar
• Du M, Wu M, Fu D, et al. Effects of modified LDL and HDL on retinal pigment epithelial cells: a role in diabetic retinopathy? Diabetologia 2013;56(10):2318–2328
   PubMed Web of Science ®Google Scholar
• Fu D, Yu JY, Wu M, et al. Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J Lipid Res 2014;55(5):860–869
   PubMed Web of Science ®Google Scholar
• Wang Q, Tikhonenko M, Bozack SN, et al. Changes in the daily rhythm of lipid metabolism in the diabetic retina. PloS ONE 2014;9(4):e95028
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Nawaz MI, Mohammad G, et al. Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy. Lipids Health Dis 2014;13:187
   PubMed Web of Science ®Google Scholar
• Njie-Mbye YF, Kulkarni-Chitnis M, et al. Lipid peroxidation: pathophysiological and pharmacological implications in the eye. Front Physiol 2013;4:366
   PubMed Web of Science ®Google Scholar
• Chan AY, Mann SN, Chen H, et al. Sphingolipids in ocular inflammation. Adv Exp Med Biol 2014;801:623–629
   PubMed Web of Science ®Google Scholar
• Kishan AU, Modjtahedi BS, Martins EN, et al. Lipids and age-related macular degeneration. Surv Ophthalmol 2011;56(3):195–213
   PubMed Web of Science ®Google Scholar
• Yu JY, Lyons TJ. Modified lipoproteins in diabetic retinopathy: a local action in the retina. J Clin Exp Ophthalmol 2013;4(6):314
   PubMedGoogle Scholar
• Ahsan H. Diabetic retinopathy—Biomolecules and multiple pathophysiology. Diabetes Metabolic Syndrome 2015;9(1):51–54
   PubMed Web of Science ®Google Scholar
• Busik JV, Esselman WJ, Reid GE. Examining the role of lipid mediators in diabetic retinopathy. Clinical Lipidol 2012;7(6):661–675
   PubMed Web of Science ®Google Scholar
• Van Eck WF. The effect of a low fat diet on the serum lipids in diabetes and its significance in diabetic retinopathy. Am J Med 1959;27:196–211
   PubMed Web of Science ®Google Scholar
• King RC, Dobree JH, Kok D, et al. Exudative diabetic retinopathy. Spontaneous changes and effects of a corn oil diet. Br J Ophthalmol 1963;47:666–672
   PubMedGoogle Scholar
• Houtsmuller AJ, Zahn KJ, Henkes HE. Unsaturated fats and progression of diabetic retinopathy. Doc Ophthalmol Adv Ophthalmol 1980;48(2):363–371
   PubMed Web of Science ®Google Scholar
• Howard-Williams J, Patel P, Jelfs R, et al. Polyunsaturated fatty acids and diabetic retinopathy. Br J Ophthalmol 1985;69(1):15–18
   PubMed Web of Science ®Google Scholar
• Duncan LJ, Cullen JF, Ireland JT, et al. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968;17(7):458–467
   PubMed Web of Science ®Google Scholar
• Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969;18(5):285–291
   PubMed Web of Science ®Google Scholar
• Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc United Kingdom. 1974;94(2):554–562
   PubMedGoogle Scholar
• Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991;112(4):385–391
   PubMed Web of Science ®Google Scholar
• Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002;56(1):1–11
   PubMed Web of Science ®Google Scholar
• Banerjee S, Denniston AK, Gibson JM, Dodson PM. Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? Eye (Lond) 2004;18(8):821–825
   PubMed Web of Science ®Google Scholar
• JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1–52
   Google Scholar
• Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004;137(4):675–682
   PubMed Web of Science ®Google Scholar
• Janknecht P, Schumann M, Hansen LL. Reduction of retinal exudates in diabetic retinopathy after heparin-induced extracorporal LDL-precipitation (HELP). A case report. Eur J Ophthalmol 1996;6(3):340–342
   Google Scholar
• Widder RA, Brunner R, Walter P, et al. Improvement of visual acuity in patients suffering from diabetic retinopathy after membrane differential filtration: a pilot study. Transfusion Sci 1999;21(3):201–206
   PubMedGoogle Scholar
• Zhang J, McGwin G Jr. Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol 2007;125(8):1096–1099
   PubMedGoogle Scholar
• Dodson PM. Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality? Eye 2009;23(5):997–1003
   PubMed Web of Science ®Google Scholar
• Dodson P. The effect of statins on diabetic retinopathy. Diabetic retinopathy—Diagnostic and treatment novelties. American Diabetes Association 66th Scientific Sessions, Washington, DC 2006
   Google Scholar
• Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370(9600):1687–1697
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889–2934
   PubMed Web of Science ®Google Scholar
• Medina RJ, O'Neill CL, Devine AB, et al. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PloS One 2008;3(7):e2584
   PubMed Web of Science ®Google Scholar
• Li J, Wang JJ, Chen D, et al. Systemic administration of HMG-CoA reductase inhibitor protects the blood–retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp Eye Res 2009;89(1):71–78
   PubMed Web of Science ®Google Scholar
• Miyahara S, Kiryu J, Yamashiro K, et al. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol 2004;164(5):1697–1706
   PubMed Web of Science ®Google Scholar
• Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49(7):3231–3238
   PubMed Web of Science ®Google Scholar
• Zheng Z, Chen H, Wang H, et al. Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor gamma coactivator 1alpha. Diabetes 2010;59(9):2315–2325
   PubMed Web of Science ®Google Scholar
• Kawahara S, Hata Y, Kita T, et al. Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes 2008;57(10):2784–2793
   PubMed Web of Science ®Google Scholar
• Ozkiris A, Erkilic K, Koc A, Mistik S. Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy. Br J Ophthalmol 2007;91(1):69–73
   PubMed Web of Science ®Google Scholar
• Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16(14):1928–1930
   PubMedGoogle Scholar
• Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38(5):604–609
   PubMed Web of Science ®Google Scholar
• Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 2003;170(2):229–236
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849–1861
   PubMed Web of Science ®Google Scholar
• Ansquer JC, Crimet D, Foucher C. Fibrates and statins in the treatment of diabetic retinopathy. Curr Pharm Biotechnol 2011;12(3):396–405
   PubMed Web of Science ®Google Scholar
• Massin P, Peto T, Ansquer JC, et al. Effects of fenofibric acid on diabetic macular edema: The MacuFen study. Ophthalmic Epidemiol 2014;21(5):307–317
   PubMed Web of Science ®Google Scholar
• Wright AD, Dodson PM. Medical management of diabetic retinopathy: Fenofibrate and ACCORD Eye studies. Eye (Lond) 2011;25(7):843–849
   PubMed Web of Science ®Google Scholar
• Simo R, Roy S, Behar-Cohen F, et al. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem 2013;20(26):3258–3266
   PubMed Web of Science ®Google Scholar
• Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010;6(8):454–463
   PubMed Web of Science ®Google Scholar
• Bishop-Bailey D. PPARs and angiogenesis. Biochem Soc Trans 2011;39(6):1601–1605
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Lin M, et al. Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 2013;62(1):261–272
   PubMed Web of Science ®Google Scholar
• Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiol Rev 2005;13(5):240–246
   PubMedGoogle Scholar
• Stottrup C, Roy, S, Rizzo, L, et al. Effect of fenofibrate on overexpression of extracellular matrix components, COX-2, and barrier permeability associated with diabetic retinopathy. IOVS 2012;53:e-abstract 480
   Google Scholar
• Barnett JM, McCollum GW, Penn JS. Role of cytosolic phospholipase A(2) in retinal neovascularization. Invest Ophthalmol Vis Sci 2010;51(2):1136–1142
   PubMed Web of Science ®Google Scholar
• Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002;90(11):1254–1257
   PubMed Web of Science ®Google Scholar
• Tomizawa A, Hattori Y, Inoue T, et al. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metab Clin Exp 2011;60(4):513–522
   PubMed Web of Science ®Google Scholar